| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, ErbB-2 | 11 | 2023 | 2650 | 1.380 |
Why?
|
| Breast Neoplasms | 20 | 2023 | 16183 | 1.010 |
Why?
|
| Curcumin | 3 | 2011 | 119 | 0.800 |
Why?
|
| Azadirachta | 2 | 2011 | 2 | 0.780 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2011 | 366 | 0.740 |
Why?
|
| Trastuzumab | 8 | 2023 | 743 | 0.700 |
Why?
|
| Plant Extracts | 2 | 2011 | 225 | 0.650 |
Why?
|
| NF-kappa B | 6 | 2011 | 1560 | 0.630 |
Why?
|
| Neuroblastoma | 4 | 2011 | 705 | 0.610 |
Why?
|
| Estrogen Receptor alpha | 4 | 2021 | 692 | 0.610 |
Why?
|
| Gamma Rays | 3 | 2011 | 237 | 0.520 |
Why?
|
| Gene Fusion | 1 | 2016 | 214 | 0.490 |
Why?
|
| Signal Transduction | 15 | 2021 | 12087 | 0.450 |
Why?
|
| Radiation, Ionizing | 2 | 2011 | 190 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 9039 | 0.440 |
Why?
|
| Rosaceae | 1 | 2011 | 2 | 0.400 |
Why?
|
| Apoptosis | 6 | 2019 | 7741 | 0.370 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 184 | 0.370 |
Why?
|
| Carrier Proteins | 2 | 2020 | 2100 | 0.360 |
Why?
|
| Digestive System | 1 | 2010 | 120 | 0.360 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 264 | 0.360 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 812 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 16640 | 0.340 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 5405 | 0.340 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 529 | 0.330 |
Why?
|
| Quinazolines | 3 | 2023 | 956 | 0.280 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 894 | 0.280 |
Why?
|
| Gene Amplification | 3 | 2019 | 766 | 0.270 |
Why?
|
| Sarcoma, Ewing | 1 | 2010 | 428 | 0.270 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 5225 | 0.260 |
Why?
|
| Genes, p53 | 1 | 2010 | 1140 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 1570 | 0.260 |
Why?
|
| Receptors, Estrogen | 5 | 2021 | 2158 | 0.250 |
Why?
|
| Genomics | 1 | 2016 | 2834 | 0.250 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2020 | 796 | 0.250 |
Why?
|
| Biomarkers, Tumor | 7 | 2023 | 10695 | 0.240 |
Why?
|
| Cell Line, Tumor | 14 | 2021 | 14832 | 0.230 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 5138 | 0.230 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 14615 | 0.230 |
Why?
|
| Mice, Nude | 4 | 2020 | 4329 | 0.210 |
Why?
|
| Protein Kinases | 2 | 2016 | 897 | 0.200 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 1555 | 0.200 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 1708 | 0.190 |
Why?
|
| Plant Leaves | 2 | 2011 | 60 | 0.190 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2011 | 751 | 0.190 |
Why?
|
| Linear Energy Transfer | 2 | 2011 | 106 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 135 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 210 | 0.170 |
Why?
|
| Mevalonic Acid | 1 | 2019 | 32 | 0.170 |
Why?
|
| Cinnamates | 1 | 2018 | 29 | 0.160 |
Why?
|
| Cell Survival | 4 | 2021 | 3056 | 0.160 |
Why?
|
| Pyrimidinones | 1 | 2020 | 318 | 0.160 |
Why?
|
| Female | 20 | 2023 | 148486 | 0.160 |
Why?
|
| Pyridones | 1 | 2020 | 360 | 0.150 |
Why?
|
| Oncogene Addiction | 1 | 2017 | 4 | 0.150 |
Why?
|
| Humans | 27 | 2023 | 270033 | 0.140 |
Why?
|
| Brain | 1 | 2010 | 4210 | 0.140 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 347 | 0.140 |
Why?
|
| Mice | 9 | 2021 | 35465 | 0.140 |
Why?
|
| Remission Induction | 2 | 2020 | 3648 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 841 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 1017 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2019 | 1272 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 3911 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1017 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 5250 | 0.110 |
Why?
|
| Open Reading Frames | 1 | 2014 | 276 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 4955 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 2308 | 0.110 |
Why?
|
| Pyridines | 1 | 2021 | 1310 | 0.110 |
Why?
|
| Prognosis | 5 | 2021 | 22451 | 0.110 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 3337 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 2391 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2016 | 520 | 0.110 |
Why?
|
| Indoles | 1 | 2018 | 1026 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 1837 | 0.110 |
Why?
|
| Animals | 9 | 2021 | 61714 | 0.100 |
Why?
|
| Cell Separation | 1 | 2014 | 608 | 0.100 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 675 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2011 | 26 | 0.100 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 2197 | 0.100 |
Why?
|
| Piperazines | 1 | 2021 | 2145 | 0.100 |
Why?
|
| Aminoquinolines | 1 | 2011 | 52 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 56 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2019 | 1207 | 0.100 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2011 | 137 | 0.100 |
Why?
|
| Gene Expression | 1 | 2020 | 3630 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 4958 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2011 | 175 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 657 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 676 | 0.090 |
Why?
|
| Infrared Rays | 1 | 2010 | 62 | 0.090 |
Why?
|
| Radiation Tolerance | 2 | 2011 | 637 | 0.090 |
Why?
|
| Aniline Compounds | 1 | 2011 | 205 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 374 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2073 | 0.090 |
Why?
|
| Fruit | 1 | 2011 | 302 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 5757 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 5061 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2018 | 7236 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 2571 | 0.080 |
Why?
|
| DNA Primers | 1 | 2010 | 1494 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3037 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 1469 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 5000 | 0.070 |
Why?
|
| Telomerase | 1 | 2011 | 546 | 0.070 |
Why?
|
| Time Factors | 2 | 2011 | 12953 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 15172 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2353 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2023 | 33691 | 0.070 |
Why?
|
| Cell Movement | 1 | 2014 | 2460 | 0.070 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 1107 | 0.070 |
Why?
|
| Phenotype | 2 | 2016 | 6485 | 0.070 |
Why?
|
| Transfection | 1 | 2011 | 3115 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 4043 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 547 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 3030 | 0.070 |
Why?
|
| Tamoxifen | 2 | 2020 | 875 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 3602 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 3468 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2010 | 1145 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 1542 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2011 | 6368 | 0.060 |
Why?
|
| Base Sequence | 1 | 2010 | 5424 | 0.060 |
Why?
|
| DNA | 1 | 2011 | 3046 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2011 | 2376 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5773 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2021 | 4939 | 0.050 |
Why?
|
| Models, Biological | 1 | 2010 | 3187 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 13996 | 0.040 |
Why?
|
| Cytokines | 1 | 2009 | 2810 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 181 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 7038 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 9040 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 383 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 275 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2016 | 2417 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 1077 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 499 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2020 | 488 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3398 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 686 | 0.030 |
Why?
|
| Dasatinib | 1 | 2020 | 881 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 78 | 0.030 |
Why?
|
| Heterografts | 1 | 2018 | 739 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 884 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 5585 | 0.030 |
Why?
|
| Estradiol | 1 | 2018 | 828 | 0.030 |
Why?
|
| Mutation | 2 | 2017 | 15900 | 0.030 |
Why?
|
| Estrogens | 1 | 2018 | 808 | 0.030 |
Why?
|
| Radiation Dosage | 2 | 2009 | 1042 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 371 | 0.030 |
Why?
|
| Breast | 1 | 2020 | 1366 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 827 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3993 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 248 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2016 | 2136 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 7883 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 2472 | 0.020 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2009 | 17 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6182 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 684 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2009 | 123 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 202 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2020 | 9288 | 0.020 |
Why?
|
| DNA Damage | 1 | 2016 | 1981 | 0.020 |
Why?
|
| Middle Aged | 3 | 2020 | 90030 | 0.020 |
Why?
|
| Genome, Human | 1 | 2016 | 1885 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 7343 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 530 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 1957 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 3896 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 874 | 0.010 |
Why?
|
| Aged | 2 | 2020 | 73127 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 3210 | 0.010 |
Why?
|
| Adult | 2 | 2020 | 81689 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 22134 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 3343 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 30923 | 0.010 |
Why?
|